<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83595">
  <stage>Registered</stage>
  <submitdate>11/02/2009</submitdate>
  <approvaldate>3/04/2009</approvaldate>
  <actrnumber>ACTRN12609000164291</actrnumber>
  <trial_identification>
    <studytitle>Gender specific responses in platelet function following long chain omega-3 fatty acid supplementation</studytitle>
    <scientifictitle>Supplementation with long chain omega-3 polyunsaturated fatty acids to reduce platelet aggregation differentially by gender in healthy volunteers</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Platelet aggregation</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Normal development and function of platelets and erythrocytes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants of equal gender are randomised to receive an oral administration of a single dose of either omega-3 fish oil capsules or placebo containing:
(i) 2 x 1g dose 500mg Docosahexaenoic Acid (DHA) [1:5 EPA/DHA] 
(ii) 2 x 1g dose 500mg Eicosapentaenoic Acid [5:1 EPA/DHA]
(iii) 2 x 1g dose Placebo (olive oil)
Participants are assessed at baseline and at post 2, 5 and 24 hours following consumption of the capsules.</interventions>
    <comparator>Oral administration of a single dose of 2 x 1g olive oil capsules</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome of this trial is to determine the gender-specific responses in platelet function (aggregation) following omega-3 fatty acid supplementation.</outcome>
      <timepoint>Blood samples from participants will be collected at the commencement of the study (prior to suppplementation) and again at 2, 5 and 24 hours following supplementation. Whole blood platelet aggregation, platelet count, biomarkers of coagulation and a complete plasma lipid profile will be generated from each blood sample.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The secondary outcome is to compare the efficacy of each individual long chain omega-3 fatty acid (Eicosapentaenoic Acid, Docosahexaenoic Acid) to inhibit platelet aggregation at each timepoint by analysis of blood samples.</outcome>
      <timepoint>All these outcomes will be measured at baseline, 2, 5 and 24 hours post intervention.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy participants aged 25 years or above.</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Participants diagnosed with any hematological or cardiovascular disorders and are taking fish oil capsules or medication affecting coagulation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/03/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The University of Newcastle</primarysponsorname>
    <primarysponsoraddress>University Drive, Callaghan Campus, New South Wales, 2308</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Professor Manohar Garg</fundingname>
      <fundingaddress>Nutraceuticals Research Group
School of Biomedical Sciences</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Professor Manohar Garg</fundingname>
      <fundingaddress>Nutraceuticals Research Group
School of Biomedical Sciences</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>The University of Newcastle</sponsorname>
      <sponsoraddress>University Drive, Callaghan Campus, New South Wales, 2308</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>The University of Newcastle</sponsorname>
      <sponsoraddress>University Drive, Callaghan Campus, New South Wales, 2308</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to determine the gender specific responses in platelet reactivity following supplementation with long chain omega-3 polyunsaturated fatty acids (LCn-3 PUFA).  It is anticipated that there will be significant gender related differences in response to different concentration ratios of long chain n-3 PUFA supplementation. 
This research study is designed to assess the effectiveness of Eicosapentaenoic Acid and Docoshexaenoic Acid to inhibit platelet aggregation in healthy males versus females. These studies will be randomised controlled trials where platelet function of healthy subjects will be monitored over the intervention period following dietary supplementation of the fish oil concentrates or placebo.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The University of Newcastle Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Office, The Chancellory, The University of Newcastle, Unversity Drive, Callaghan, New South Wales, 2308</ethicaddress>
      <ethicapprovaldate>20/06/2008</ethicapprovaldate>
      <hrec>H-2008-0149</hrec>
      <ethicsubmitdate>5/05/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Manohar Garg</name>
      <address>Nutraceuticals Research Group
School of Biomedical Sciences
305C Medical Sciences Building
The University of Newcastle, Callaghan
New South Wales 2308</address>
      <phone>+61 2 49215647</phone>
      <fax />
      <email>manohar.garg@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Melinda Phang</name>
      <address>Nutraceuticals Research Group
School of Biomedical Sciences
305 Medical Sciences Building
The University of Newcastle, Callaghan
New South Wales 2308</address>
      <phone>+61 2 49215636</phone>
      <fax />
      <email>melinda.phang@studentmail.newcastle.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>